BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

Beijing Tong Ren Tang Chinese Medicine Company Limited

3613

HK0000145638

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:00 2024-05-03 am EDT			5-day change	1st Jan Change
9.42 ^HKD	+0.32%		-1.88%	-22.41%

Apr. 30	Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong	MT
Mar. 29	Beijing Tong Ren Tang Chinese Medicine CEO Steps Down; Acting CEO Appointed	MT

Beijing Tong Ren Tang Chinese Medicine Company Limited Propose Payment of A Final Dividend

March 28, 2018 at 05:28 am EDT

Beijing Tong Ren Tang Chinese Medicine Company Limited announced that at AGM the company will propose payment of a final dividend of 19 HK cents per share for the year ended 31 December 2017.

Latest news about Beijing Tong Ren Tang Chinese Medicine Company Limited

Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong	Apr. 30	MT
Beijing Tong Ren Tang Chinese Medicine CEO Steps Down; Acting CEO Appointed	Mar. 28	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes	Mar. 28	CI
Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Yu Jin as an Executive Director and Member of the Competition Executive Committee	Mar. 28	CI
Beijing Tong Ren Tang Chinese Medicine's Profit Falls on Lower Revenue	Mar. 15	MT
Beijing Tong Ren Tang Chinese Medicine Signs E-Commerce Framework Agreement	Mar. 15	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on June 17,2024	Mar. 14	CI
Beijing Tong Ren Tang Chinese Medicine Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Beijing Tong Ren Tang Flags Up to 22% Profit Drop in 2023	Jan. 29	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 29	CI
Beijing Tong Ren Tang Appoints Chairman	Dec. 13	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative	Dec. 13	CI
Beijing Tong Ren Tang to Vote Dec. 27 on Renewal of Distributorship Contracts	Dec. 05	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes New Exclusive Distributorship Framework Agreements	Nov. 29	CI
Chinese listed firms used endangered animal parts as ingredients -report	23-10-23	RE
Three listed Chinese firms used endangered animal parts as ingredients- report	23-10-22	RE
Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Mr. Yu Jin as Executive Director and A Member of Competition Executive Committee	23-10-20	CI
Sinopharm CFO Retires; Successor Named	23-10-16	MT
Beijing Tong Ren Tang Chinese Medicine COO Resigns	23-09-12	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee	23-09-12	CI
Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board	23-08-31	CI
Beijing Tong Ren Tang's Profit Jumps 23.9% in H1	23-08-11	MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-10	CI
Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022	23-05-08	CI
Beijing Tong Ren Tang Chinese Medicine’s CEO Redesignated; New CEO Named	23-04-19	MT

Chart Beijing Tong Ren Tang Chinese Medicine Company Limited

Duration

Period

Chart Beijing Tong Ren Tang Chinese Medicine Company Limited

More charts

Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. It is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Tong Ren Tang Chinese Medicine Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.42 HKD

Average target price

13.92 HKD

Spread / Average Target

+47.82%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED	-22.41%	1.01B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B

Other Pharmaceuticals